Global Health Innovation Act of 2015

Bill: 114-hr-2241
Sponsor: full_name: Rep. Sires, Albio [D-NJ-8]
Introduced: 2015-05-05
Policy area: International Affairs
Subjects: Child health

Congressional oversight

Drug therapy

Foreign aid and international relief

HIV/AIDS

Health programs administration and funding

Health promotion and preventive care

Health technology, devices, supplies

Immunology and vaccination

Infectious and parasitic diseases

Medical tests and diagnostic methods

Product development and innovation

Public-private cooperation

U.S. Agency for International Development (USAID)

Women's health

World health
Latest action: action_date: 2015-12-18
text: Received in the Senate and Read twice and referred to the Committee on Foreign Relations.

Summaries:
action_date: 2015-05-05
action_desc: Introduced in House
text: <p><strong>Global Health Innovation Act of 2015</strong></p> <p>This bill directs the Administrator of the U.S. Agency for International Development (USAID) to report annually to Congress on the development and use of global health innovations in USAID programs, projects, and activities.</p>

action_date: 2015-12-18
action_desc: Passed House amended
text: <p><strong>Global Health Innovation Act of 2015</strong></p> <p>(Sec. 2) This bill directs the U.S. Agency for International Development (USAID) to report annually for four years to Congress regarding: </p> <ul> <li>the extent to which global health innovations include drugs, diagnostics, devices, vaccines, electronic and mobile health technologies, and related behavior change and service delivery innovations; </li> <li>how innovation has advanced USAID's commitments to achieving an HIV/AIDS-free generation, ending preventable child and maternal deaths, and protecting communities from infectious diseases;</li> <li>how goals are set for health product development in relation to USAID's health-related goals; </li> <li> how USAID is leveraging U.S. investments to achieve greater impact in health innovation, developing and introducing affordable global health products, and increasing health innovations in the development pipeline; </li> <li>how USAID is coordinating with other federal departments and agencies in support of global health product development; and </li> <li> how USAID is coordinating and aligning global health innovation activities between the Global Development Lab, the Center for Accelerating Innovation and Impact, and the Bureau for Global Health.</li></ul>

tv_txt: I 114th CONGRESS 1st Session H. R. 2241 IN THE HOUSE OF REPRESENTATIVES May 5, 2015 Mr. Sires (for himself and Mr. Diaz-Balart ) introduced the following bill; which was referred to the Committee on Foreign Affairs A BILL To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

1. Short title This Act may be cited as the Global Health Innovation Act of 2015 . 2. Annual report (a) In general Not later than 180 days after the date of the enactment of this Act, and annually thereafter, the Administrator of the United States Agency for International Development shall submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency. (b) Matters To Be Included The report required by subsection (a) shall include the following: (1) A description of— (A) the extent to which global health innovations described in subsection (a) include drugs, diagnostics, devices, vaccines, electronic and mobile health technologies, and related behavior change and service delivery innovations; (B) how innovation has advanced the Agency’s commitments to achieving an HIV/AIDS-free generation, ending preventable child and maternal deaths, and protecting communities from infectious diseases, as well as furthered by the Global Health Strategic Framework; (C) how goals are set for health product development in relation to the Agency’s health-related goals and how progress and impact are measured towards those goals; (D) how the Agency’s investments in innovation relate to its stated goals; and (E) progress made towards health product development goals. (2) How the Agency both, independently and with partners, donors, and public-private partnerships, is— (A) leveraging United States investments to achieve greater impact in health innovation; (B) engaging in activities to develop, advance, and introduce affordable, available, and appropriate global health products; and (C) scaling up appropriate health innovations in the development pipeline. (3) A description of collaboration and coordination with other Federal departments and agencies, including the Centers for Disease Control and Prevention, in support of global health product development, including a description of how the Agency is working to ensure critical gaps in product development for global health are being filled. (4) A description of how the Agency is coordinating and aligning global health innovation activities between the Global Development Lab, the Center for Accelerating Innovation and Impact, and the Bureau for Global Health.

tv_txt: I 114th CONGRESS 1st Session H. R. 2241 IN THE HOUSE OF REPRESENTATIVES AN ACT To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

1. Short title This Act may be cited as the Global Health Innovation Act of 2015 . 2. Annual report (a) In general Not later than 180 days after the date of the enactment of this Act, and annually thereafter for a period of 4 years, the Administrator of the United States Agency for International Development shall submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency. (b) Matters To Be Included The report required by subsection (a) shall include the following: (1) A description of— (A) the extent to which global health innovations described in subsection (a) include drugs, diagnostics, devices, vaccines, electronic and mobile health technologies, and related behavior change and service delivery innovations; (B) how innovation has advanced the Agency’s commitments to achieving an HIV/AIDS-free generation, ending preventable child and maternal deaths, and protecting communities from infectious diseases, as well as furthered by the Global Health Strategic Framework; (C) how goals are set for health product development in relation to the Agency’s health-related goals and how progress and impact are measured towards those goals; (D) how the Agency’s investments in innovation relate to its stated goals; and (E) progress made towards health product development goals. (2) How the Agency both, independently and with partners, donors, and public-private partnerships, is— (A) leveraging United States investments to achieve greater impact in health innovation; (B) engaging in activities to develop, advance, and introduce affordable, available, and appropriate global health products; and (C) scaling up appropriate health innovations in the development pipeline. (3) A description of collaboration and coordination with other Federal departments and agencies, including the Centers for Disease Control and Prevention, in support of global health product development, including a description of how the Agency is working to ensure critical gaps in product development for global health are being filled. (4) A description of how the Agency is coordinating and aligning global health innovation activities between the Global Development Lab, the Center for Accelerating Innovation and Impact, and the Bureau for Global Health.

Passed the House of Representatives December 18, 2015. Karen L. Haas, Clerk.

tv_txt: IIB 114th CONGRESS 1st Session H. R. 2241 IN THE SENATE OF THE UNITED STATES December 18, 2015 Received; read twice and referred to the Committee on Foreign Relations AN ACT To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

1. Short title This Act may be cited as the Global Health Innovation Act of 2015 . 2. Annual report (a) In general Not later than 180 days after the date of the enactment of this Act, and annually thereafter for a period of 4 years, the Administrator of the United States Agency for International Development shall submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency. (b) Matters To Be Included The report required by subsection (a) shall include the following: (1) A description of— (A) the extent to which global health innovations described in subsection (a) include drugs, diagnostics, devices, vaccines, electronic and mobile health technologies, and related behavior change and service delivery innovations; (B) how innovation has advanced the Agency’s commitments to achieving an HIV/AIDS-free generation, ending preventable child and maternal deaths, and protecting communities from infectious diseases, as well as furthered by the Global Health Strategic Framework; (C) how goals are set for health product development in relation to the Agency’s health-related goals and how progress and impact are measured towards those goals; (D) how the Agency’s investments in innovation relate to its stated goals; and (E) progress made towards health product development goals. (2) How the Agency both, independently and with partners, donors, and public-private partnerships, is— (A) leveraging United States investments to achieve greater impact in health innovation; (B) engaging in activities to develop, advance, and introduce affordable, available, and appropriate global health products; and (C) scaling up appropriate health innovations in the development pipeline. (3) A description of collaboration and coordination with other Federal departments and agencies, including the Centers for Disease Control and Prevention, in support of global health product development, including a description of how the Agency is working to ensure critical gaps in product development for global health are being filled. (4) A description of how the Agency is coordinating and aligning global health innovation activities between the Global Development Lab, the Center for Accelerating Innovation and Impact, and the Bureau for Global Health.

Passed the House of Representatives December 18, 2015. Karen L. Haas, Clerk